MedTrace Logo

Molecular Profiling in Lung Cancer Patients

NCT00191308 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-10-21

Study results available
· View outcomes & findings →

Summary

The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment.

Conditions

Interventions

DRUG

pemetrexed

500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

DRUG

cisplatin

75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

PROCEDURE

Radical Non-Small Cell Lung Cancer (NSCLC) surgery

All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/ GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-07-31
Completion
2010-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00191308 on ClinicalTrials.gov